Table 2 Effects of different classification of BRCA1/2 and all HR genes mutation on chemotherapy response
From: Multigene germline and somatic testing for epithelial ovarian cancer in China
Genes | Chemosensitivity | p-value | Chemosensitivity | p-value | ||
|---|---|---|---|---|---|---|
Sensitive, N = 190 n (%) | Non-sensitive†, N = 37 n (%) | Sensitive, N = 190 n (%) | Non-sensitive, N = 37 n (%) | |||
Germline | LP+ | VUS+ | ||||
BRCA1 | 38 (20.0) | 3 (8.1) | 0.137 | 47 (24.7) | 3 (8.1) | 0.044 |
BRCA2 | 8 (4.2) | 0 (0.0) | 0.433 | 18 (9.5) | 0 (0.0) | 0.106 |
BRCA1/2 | 45 (23.7) | 3 (8.1) | 0.057 | 61 (32.1) | 3 (8.1) | 0.006 |
HRo | 6 (3.2) | 0 (0.0) | 0.593 | 40 (21.1) | 9 (24.3) | 0.823 |
HR | 50 (26.3) | 3 (8.1) | 0.029 | 90 (47.4) | 12 (32.4) | 0.136 |
non-HR | 0 (0.0) | 1 (2.7) | 0.163 | 30 (15.8) | 9 (24.3) | 0.307 |
Somatic | ||||||
BRCA1 | 12 (6.3) | 1 (2.7) | 0.632 | 13 (6.8) | 1 (2.7) | 0.559 |
BRCA2 | 6 (3.2) | 0 (0.0) | 0.593 | 10 (5.3) | 0 (0.0) | 0.322 |
BRCA1/2 | 17 (8.9) | 1 (2.7) | 0.340 | 21 (11.1) | 1 (2.7) | 0.205 |
HRo | 15 (7.9) | 1 (2.7) | 0.437 | 23 (12.1) | 1 (2.7) | 0.159 |
HR | 30 (15.8) | 2 (5.4) | 0.161 | 40 (21.1) | 2 (5.4) | 0.044 |
non-HR | 131 (68.9) | 23 (62.2) | 0.538 | 131 (68.9) | 24 (64.9) | 0.768 |
Somatic + Germline | ||||||
BRCA1 | 50 (26.3) | 4 (10.8) | 0.069 | 60 (31.6) | 4 (10.8) | 0.018 |
BRCA2 | 14 (7.4) | 0 (0.0) | 0.183 | 28 (14.7) | 0 (0.0) | 0.026 |
BRCA1/2 | 61 (32.1) | 4 (10.8) | 0.015 | 80 (42.1) | 4 (10.8) | 0.001 |
HRo | 20 (10.5) | 1 (2.7) | 0.233 | 56 (29.5) | 10 (27.0) | 0.919 |
HR | 76 (40.0) | 5 (13.5) | 0.004 | 116 (61.1) | 13 (35.1) | 0.006 |
non-HR | 131 (68.9) | 23 (62.2) | 0.538 | 141 (74.2) | 28 (75.7) | 1.000 |
